Alzamend Neuro, Inc.(ALZN)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.0M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
ALZN Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Alzamend Neuro, Inc. (ALZN), a Healthcare sector company. ALZN is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.0m in revenue. Based on the latest XBRL financial filings (Q3 2026), Alzamend Neuro, Inc. reports net income of $-2.2M, free cash flow of $-1.7M. Top institutional holders of ALZN by reported 13-F value include GEODE CAPITAL MANAGEMENT,, VANGUARD FIDUCIARY CO, MORGAN STANLEY, based on the most recent SEC filings. ALZN trades on the Nasdaq exchange and files with the SEC under CIK 1677077. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALZN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Alzamend Neuro, Inc. directly from SEC EDGAR.
Net Income
Q3 2026
$-2.2M
Free Cash Flow
Q3 2026
$-1.7M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
+69.7% YoYOperating Income
+69.8% YoYEPS (Diluted)
-4845.4% YoYTotal Assets
-22.2% YoYOp. Cash Flow
+26.4% YoY| Metric | FY 2025 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|
| Net Income | $-4.5M +69.7% | $-14.9M -20.4% | $-12.4M -145.0% | $-5.0M -14.4% | $-4.4M | — |
| Operating Income | $-4.5M +69.8% | $-14.9M -20.7% | $-12.3M -148.8% | $-5.0M -11.9% | $-4.4M | — |
| EPS (Diluted) | $-11.32 -4845.4% | $-0.23 -16250.0% | $-0.00 | — | — | — |
| Total Assets | $4.6M -22.2% | $5.9M -59.2% | $14.5M +398.4% | $2.9M +60.6% | $1.8M | — |
| Operating Cash Flow | $-6.6M +26.4% | $-8.9M -34.9% | $-6.6M -143.9% | $-2.7M -15.6% | $-2.3M | — |
Get alerted when ALZN's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Alzamend Neuro, Inc. including:
Top Institutional Holders of ALZN
GEODE CAPITAL MANAGEMENT, LLC
$48.4K45,680 shVANGUARD FIDUCIARY TRUST CO
$22.3K21,020 shMORGAN STANLEY
$19.1K18,000 shClearstead Advisors, LLC
$10.6K10,000 shTower Research Capital LLC (TRC)
$6.6K6,184 shCITIGROUP INC
$5.5K5,231 shUBS Group AG
$4.8K4,504 shVANGUARD CAPITAL MANAGEMENT LLC
$4.7K4,400 shBlackRock, Inc.
$463.00437 shSBI Securities Co., Ltd.
$23.0022 sh
| Fund | Value | Shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | $48.4K | 45,680 |
| VANGUARD FIDUCIARY TRUST CO | $22.3K | 21,020 |
| MORGAN STANLEY | $19.1K | 18,000 |
| Clearstead Advisors, LLC | $10.6K | 10,000 |
| Tower Research Capital LLC (TRC) | $6.6K | 6,184 |
| CITIGROUP INC | $5.5K | 5,231 |
| UBS Group AG | $4.8K | 4,504 |
| VANGUARD CAPITAL MANAGEMENT LLC | $4.7K | 4,400 |
| BlackRock, Inc. | $463.00 | 437 |
| SBI Securities Co., Ltd. | $23.00 | 22 |
More Healthcare Companies
View all Healthcare →Put ALZN on your watchlist
Track score changes the day Alzamend Neuro, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is ALZN a good stock to buy?
13F Pro's AI-powered analysis of Alzamend Neuro, Inc. (ALZN) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for ALZN are available on the ALZN stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own ALZN?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling ALZN. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Alzamend Neuro, Inc.'s investment landscape.